Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

5.880 USD -0.220 (-3.61%)
Official Closing Price Updated: 4:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aclaris Therapts

< Previous 1 2 3 4 5 6 7 8 9 Next >
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?
InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. 
From PR Newswire
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
From GlobeNewswire News Releases
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
From GlobeNewswire News Releases
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
Silverback Therapeutics Expands Executive Team with Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer 
From Business Wire News Releases
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatiti
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
From GlobeNewswire News Releases
Thinking about buying stock in Biocept, TOP Ships, Aclaris Therapeutics, Seanergy Maritime, or InnerWorkings?
InvestorsObserver issues critical PriceWatch Alerts for BIOC, TOPS, ACRS, SHIP, and INWK. 
From PR Newswire
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics Secures $11 Million Term Loan Facility
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
From GlobeNewswire News Releases
NASDAQ: ACRS Long Term Investor Alert: Investigation of Potential Wrongdoing at Aclaris Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 12/12/2019 -- An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares over possible breaches of fiduciary duty by... 
From SBWire - Latest Press Releases
Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)
Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company's officers and directors for breaches of... 
From Business Wire News Releases
Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)
Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company's officers and directors for breaches of... 
From Business Wire News Releases
Aclaris Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
From GlobeNewswire News Releases
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
From GlobeNewswire News Releases
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Divestiture of RHOFADE®
From GlobeNewswire News Releases
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
From GlobeNewswire News Releases
Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.